Adaptor Protein ShcD/
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
25
02
2020
revised:
26
11
2020
accepted:
14
01
2021
pubmed:
27
1
2021
medline:
27
1
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
Gliomas are characterized by diffuse infiltration of tumor cells into surrounding brain tissue, and this highly invasive nature contributes to disease recurrence and poor patient outcomes. The molecular mechanisms underlying glioma cell invasion remain incompletely understood, limiting development of new targeted therapies. Here, we have identified phosphotyrosine adaptor protein ShcD as upregulated in malignant glioma and shown that it associates with receptor tyrosine kinase Tie2 to facilitate invasion. In human glioma cells, we find that expression of ShcD and Tie2 increases invasion, and this significant synergistic effect is disrupted with a ShcD mutant that cannot bind Tie2 or hyperphosphorylate the receptor. Expression of ShcD and/or Tie2 further increases invadopodia formation and matrix degradation in U87 glioma cells. In a coculture model, we show that U87-derived tumor spheroids expressing both ShcD and Tie2 display enhanced infiltration into cerebral organoids. Mechanistically, we identify changes in focal adhesion kinase phosphorylation in the presence of ShcD and/or Tie2 in U87 cells upon Tie2 activation. Finally, we identify a strong correlation between transcript levels of ShcD and Tie2 signaling components as well as N-cadherin in advanced gliomas and those with classical or mesenchymal subtypes, and we show that elevated expression of ShcD correlates with a significant reduction in patient survival in higher grade gliomas with mesenchymal signature. Altogether, our data highlight a novel Tie2-ShcD signaling axis in glioma cell invasion, which may be of clinical significance. IMPLICATIONS: ShcD cooperates with Tie2 to promote glioma cell invasion and its elevated expression correlates with poor patient outcome in advanced gliomas.
Identifiants
pubmed: 33495401
pii: 1541-7786.MCR-20-0188
doi: 10.1158/1541-7786.MCR-20-0188
pmc: PMC10290522
mid: NIHMS1667183
doi:
Substances chimiques
SHC4 protein, human
0
Shc Signaling Adaptor Proteins
0
Receptor, TIE-2
EC 2.7.10.1
TEK protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
757-770Subventions
Organisme : NIMH NIH HHS
ID : R01 MH120227
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Neoplasia. 1999 Aug;1(3):208-19
pubmed: 10935475
Biochem J. 2012 Oct 1;447(1):1-16
pubmed: 22970934
Oncotarget. 2010 Dec;1(8):700-9
pubmed: 21321379
J Biol Chem. 2004 Mar 26;279(13):13224-33
pubmed: 14665640
BMC Bioinformatics. 2006 Jul 27;7:365
pubmed: 16872538
Nat Rev Mol Cell Biol. 2001 Apr;2(4):257-67
pubmed: 11283723
Cell Rep. 2019 Mar 19;26(12):3203-3211.e5
pubmed: 30893594
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Neurotherapeutics. 2017 Apr;14(2):284-297
pubmed: 28281173
Cell Signal. 2010 Apr;22(4):676-83
pubmed: 20026268
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cell Death Dis. 2014 Aug 14;5:e1379
pubmed: 25118939
Cancer Res. 2006 Jan 15;66(2):775-83
pubmed: 16424009
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
J Biol Chem. 2017 Apr 7;292(14):5748-5759
pubmed: 28213521
Trends Cell Biol. 2017 Aug;27(8):595-607
pubmed: 28412099
Cancer Cell. 2008 Oct 7;14(4):299-311
pubmed: 18835032
Mol Cancer Res. 2006 Dec;4(12):915-26
pubmed: 17189382
J Biol Chem. 1999 Oct 22;274(43):30896-905
pubmed: 10521483
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
Mol Cell Biol. 2003 Apr;23(8):2658-68
pubmed: 12665569
Cardiovasc Res. 2001 Feb 16;49(3):659-70
pubmed: 11166279
Oncogene. 1992 Aug;7(8):1471-80
pubmed: 1630810
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Mol Cell Biol. 2007 Jul;27(13):4759-73
pubmed: 17452444
Mol Psychiatry. 2020 Nov;25(11):2712-2727
pubmed: 31988434
J Proteome Res. 2019 Feb 1;18(2):623-632
pubmed: 30450911
Br J Cancer. 1998;77(1):51-6
pubmed: 9459145
J Cell Sci. 2018 Jan 8;131(1):
pubmed: 29311151
Mol Cell Biol. 1994 Apr;14(4):2777-85
pubmed: 7511210
Transl Oncol. 2018 Dec;11(6):1406-1418
pubmed: 30219696
Mol Biol Cell. 2014 Mar;25(6):739-52
pubmed: 24430869
J Cell Sci. 2014 Apr 15;127(Pt 8):1712-25
pubmed: 24496451
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Korean Med Sci. 2006 Apr;21(2):272-8
pubmed: 16614513
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9
pubmed: 12861074
J Biol Chem. 2018 Jan 12;293(2):623-637
pubmed: 29162725
Oncotarget. 2016 Mar 29;7(13):16146-57
pubmed: 26910374
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
J Biol Chem. 2013 Jan 18;288(3):1500-10
pubmed: 23188823
Cell Rep. 2018 Apr 24;23(4):1220-1229
pubmed: 29694897
N Engl J Med. 2008 Oct 23;359(17):1850; author reply 1850
pubmed: 18946076
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Am J Pathol. 2005 Mar;166(3):843-55
pubmed: 15743796
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Oncotarget. 2014 Apr 30;5(8):2208-20
pubmed: 24809734
Cancer Res. 2007 Apr 1;67(7):3064-73
pubmed: 17409413
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Am J Pathol. 2004 Feb;164(2):467-76
pubmed: 14742253
Nucleic Acids Res. 2015 Jan;43(Database issue):D204-12
pubmed: 25348405
J Cell Biol. 2009 Apr 20;185(2):357-70
pubmed: 19364917
Mol Cell Biol. 2001 Jun;21(12):4016-31
pubmed: 11359909
Structure. 2000 Nov 15;8(11):1105-13
pubmed: 11080633
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Curr Opin Cell Biol. 2006 Oct;18(5):516-23
pubmed: 16919435
Sci Data. 2017 Mar 14;4:170024
pubmed: 28291232
Cancer Res. 2013 Jan 1;73(1):108-18
pubmed: 23149917